A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
What is the purpose of this trial?
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.
- Trial withAstex Pharmaceuticals, Inc.
- Start Date06/14/2022
- End Date06/01/2023
- Last Updated06/15/2022
- Study HIC#2000022408